Brokerages Set Enhabit, Inc. (NYSE:EHAB) Price Target at $8.75

Shares of Enhabit, Inc. (NYSE:EHAB) have been given a consensus rating of “Hold” by the six research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $8.75.

Several research analysts have weighed in on EHAB shares. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and upped their target price for the stock from $8.25 to $9.50 in a research report on Monday, December 9th. Leerink Partners reaffirmed a “market perform” rating and issued a $8.00 price target (down previously from $8.50) on shares of Enhabit in a report on Tuesday, November 19th.

Enhabit Trading Up 1.0 %

Shares of EHAB opened at $8.55 on Thursday. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The firm’s 50-day moving average is $8.16 and its two-hundred day moving average is $7.90. Enhabit has a twelve month low of $6.85 and a twelve month high of $11.74. The firm has a market capitalization of $430.13 million, a P/E ratio of -3.69 and a beta of 1.83.

Insider Buying and Selling at Enhabit

In other news, Director Stuart M. Mcguigan acquired 15,000 shares of Enhabit stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average price of $8.81 per share, with a total value of $132,150.00. Following the completion of the purchase, the director now owns 46,810 shares of the company’s stock, valued at approximately $412,396.10. This represents a 47.15 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Bolton acquired 4,000 shares of Enhabit stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the purchase, the director now directly owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. This trade represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Enhabit

Several institutional investors and hedge funds have recently modified their holdings of the company. PharVision Advisers LLC purchased a new position in Enhabit during the fourth quarter worth approximately $317,000. Squarepoint Ops LLC purchased a new position in Enhabit during the fourth quarter worth approximately $185,000. Two Sigma Advisers LP raised its stake in Enhabit by 40.1% during the fourth quarter. Two Sigma Advisers LP now owns 27,600 shares of the company’s stock worth $216,000 after purchasing an additional 7,900 shares during the period. State of Wyoming raised its stake in Enhabit by 95.7% during the fourth quarter. State of Wyoming now owns 71,307 shares of the company’s stock worth $557,000 after purchasing an additional 34,861 shares during the period. Finally, Systematic Financial Management LP raised its stake in Enhabit by 8.6% during the fourth quarter. Systematic Financial Management LP now owns 1,996,113 shares of the company’s stock worth $15,590,000 after purchasing an additional 157,914 shares during the period.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.